4EGI-1

eIF inhibitor



ALX-430-155-M002	2 mg	186.00 USD

Selective and cell permeable inhibitor of the interaction between the human eukaryotic translation initiation factors 4E (eIF4E) and 4G (eIF4G).

Product Specification

Alternative Name:	α-[2-[4-(3,4-Dichlorophenyl)-2-thiazolyl]hydrazinylidene]-2-nitro-benzenepropanoic acid

Identity:	Identity determined by MS, ¹H- and ¹³C-NMR.

Formula:	C₁₈H₁₂Cl₂N₄O₄S

MW:	451.3

Purity:	≥95%

Appearance:	Brown solid.

CAS:	315706-13-9

Solubility:	Soluble in DMSO.

Long Term Storage:	-20°C

Handling:	Protect from light.

Please mouse over

Product Literature References

Spinal protein kinase M zeta underlies the maintenance mechanism of persistent nociceptive sensitization: M.N. Asiedu, et al.; J. Neurosci. 31, 6646 (2011), Abstract; Full Text

BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent protein synthesis: F. Grespi, et al.; Cell Death Differ. 17, 1672 (2010), Abstract; Full Text

IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex: O.K. Melemedjian, et al.; J. Neurosci. 30, 15113 (2010), Abstract; Full Text

The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation: S. Fan, et al.; Neoplasia 12, 346 (2010), Abstract;

Uncoupling stress granule assembly and translation initiation inhibition: S. Mokas, et al.; Mol. Biol. Cell 20, 2673 (2009), Abstract; Full Text

Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G: N.J. Moerke, et al.; Cell 128, 257 (2007), Abstract;